MedTrace Logo

MK0767 in Metabolic Syndrome-Dyslipidemia (0767-016)

NCT00703690 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 436

Last updated 2015-06-12

No results posted yet for this study

Summary

This is a clinical trial in patients with Metabolic Syndrome and Dyslipidemia to study the effects of MK0767 on triglycerides.

Conditions

  • Metabolic X Syndrome Dyslipidemia

Interventions

DRUG

MK0767

MK0767 2.5, 5, and 10 mg/day supplied as tablets

DRUG

Comparator: fenofibrate

fenofibrate 200 mg supplied as capsules

DRUG

Comparator: Placebo (unspecified)

matching placebo will be supplied as tablets/capsules.

Sponsors & Collaborators

Principal Investigators

  • Medical Monitor · Merck Sharp & Dohme LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-01-31
Primary Completion
2003-12-31
Completion
2003-12-31

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00703690 on ClinicalTrials.gov